卡非佐米联合免疫调节药物治疗新诊断多发性骨髓瘤综述
本综述检索PubMed及2012年1月至2018年12月主要血液/肿瘤会议摘要,纳入9篇文章和72篇摘要,评估卡非佐米联合免疫调节药物治疗新诊断多发性骨髓瘤的前瞻性临床研究;共12项试验评价6种不同联合方案,显示深度缓解(包括高微小残留病阴性率)、长无进展生存和总生存,安全性与其在复发难治多发性骨髓瘤中观察到的特征一致。
要点
- 卡非佐米联合免疫调节药物在新诊断多发性骨髓瘤中显示深度缓解,包括高微小残留病阴性率。
- 深度缓解转化为长无进展生存和总生存,疗效在年龄、移植资格和细胞遗传学风险亚组中基本一致。
- KRd方案是前线治疗中实现长期深度缓解(功能性治愈)的有前景的药物骨架。
核心结论
- 卡非佐米联合免疫调节药物在新诊断多发性骨髓瘤中高度活跃且安全性良好,KRd药物骨架是前线治疗中实现长期深度缓解(功能性治愈)的有前景基础。
研究设计与样本
- 本综述检索PubMed索引文章及2012年1月至2018年12月主要血液/肿瘤会议摘要,纳入评估卡非佐米联合免疫调节药物治疗新诊断多发性骨髓瘤的前瞻性临床研究,共纳入9篇文章和72篇摘要。
- 共12项临床试验评价了6种不同的基于卡非佐米的蛋白酶体抑制剂/免疫调节药物联合方案。
主要发现
- 这些方案治疗总体带来深度缓解,包括高微小残留病阴性率。
- 深度缓解转化为长无进展生存和总生存率。
- 疗效结果在年龄、移植资格和细胞遗传学风险定义的亚组中基本一致。
- 卡非佐米在新诊断多发性骨髓瘤中的安全性特征与其在复发难治多发性骨髓瘤中观察到的特征一致。
关键数值与推荐
- 共纳入9篇文章和72篇摘要,评价12项临床试验中的6种不同联合方案。
- 检索时间范围为2012年1月至2018年12月。
临床怎么用
- 卡非佐米联合免疫调节药物可用于新诊断多发性骨髓瘤的前线治疗策略,KRd骨架是其中一种有前景的基础方案。
- 多项正在进行的 study 正在评估KRd联合或不联合抗CD38单克隆抗体。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carfilzomib, a selective proteasome inhibitor (PI), is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). Combination regimens incorporating a PI and immunomodulatory drug (IMiD) have been associated with deep responses and extended survival in patients with newly diagnosed MM (NDMM). Carfilzomib-based combinations with immunomodulators are being extensively studied in the frontline setting. The objective of this review was to describe efficacy and safety data for carfilzomib-based, PI/immunomodulatory combinations in NDMM. Information sources were articles indexed in PubMed and abstracts from key hematology/oncology congresses published between January 2012 and December 2018. PubMed and congresses were searched for prospective clinical studies assessing the combination of carfilzomib with an IMiD for NDMM treatment. Retrospective and preclinical reports, case reports/series, reviews, and clinical studies not evaluating carfilzomib-immunomodulator combinations in NDMM were excluded based on review of titles and abstracts. A total of nine articles and 72 abstracts were deemed relevant and included in the review. A total of six distinct carfilzomib-based, PI/immunomodulator combination regimens have been evaluated in 12 clinical trials. Overall, treatment with these regimens has resulted in deep responses, including high rates of negativity for minimal residual disease. These deep responses have translated to long progression-free survival and overall survival rates. Efficacy results for these regimens have generally been consistent across subgroups defined by age, transplant eligibility, and cytogenetic risk. The safety profile of carfilzomib in NDMM is consistent with that observed in the relapsed-refractory MM setting. Clinical studies have found that carfilzomib-based combinations with immunomodulators are highly active with a favorable safety profile in NDMM. The carfilzomib, lenalidomide, and dexamethasone (KRd) drug backbone is a promising foundation for treatment strategies aimed at achieving long-term, deep responses (functional cures) in the frontline setting. Several ongoing studies are evaluating KRd, with or without anti-CD38 monoclonal antibodies.
引用
- Landgren O, Sonneveld P, Jakubowiak A, et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019. PMID: 31341235. doi:10.1038/s41375-019-0517-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。